Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)
Open Access

Development of Flourinated NP-59: A Revival of Cholesterol Utilization Imaging with PET

Allen L Brooks, Wade Winton, Jenelle Stauff, Janna Arteaga, Bradford Henderson, Jeremy Niedbala, Peter Scott and Benjamin L Viglianti
Journal of Nuclear Medicine April 2022, jnumed.122.263864; DOI: https://doi.org/10.2967/jnumed.122.263864
Allen L Brooks
University of Michigan, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wade Winton
University of Michigan, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenelle Stauff
University of Michigan, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janna Arteaga
University of Michigan, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradford Henderson
University of Michigan, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Niedbala
University of Michigan, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Scott
University of Michigan, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin L Viglianti
University of Michigan, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Imaging of cholesterol utilization is possible with the iodine-131 scintiscanning/SPECT agent, NP-59. This agent provided a non-invasive measure of adrenal function and steroid synthesis. However, iodine isotopes resulted in poor resolution, manufacturing challenges, and high radiation dosimetry to patients that have limited their use and clinical impact. A fluorine-18 analogue would address these shortcomings while retaining the ability to image cholesterol utilization. Purpose: The goal of this study was to prepare and evaluate a fluorine-18 analogue of NP-59 to serve as a PET imaging agent for functional imaging of the adrenal glands based on cholesterol use. Previous attempts to prepare such an analogue of NP-59 have proven elusive. Preclinical and clinical evaluation could be carried out once the new fluorine analogue of NP-59 production was established. Methods: The recent development of a new reagent for fluorination along with an improved route to the NP-59 precursor allowed for the preparation of a fluorine analogue of NP-59, FNP-59. The radiochemistry for the fluorine-18 radiolabeled 18F-FNP-59 is described, rodent radiation dosimetry studies and in vivo imaging in New Zealand rabbits was carried out. After in vivo toxicity studies, an IND approval was obtained and the first in human images with dosimetry using the agent were acquired. Results: In vivo toxicity studies demonstrated that FNP-59 is safe for use at intended dose. Biodistribution studies with 18F-FNP-59 demonstrated a similar pharmacokinetic profile to NP-59, but with decreased radiation exposure. In vivo animal images demonstrate expected uptake in tissues that utilize cholesterol: gallbladder, liver, and adrenal glands. First in human images had no adverse events and demonstrated accumulation in target tissues (liver and adrenal glands). Manipulation of uptake was also demonstrated with patients that received cosyntropin, resulting in improved uptake. Conclusion: 18F-FNP-59 provided higher resolution images, with lower radiation dose to the subjects. It has the potential to provide a non-invasive test for patients with adrenocortical diseases.

  • Endocrine
  • Radiobiology/Dosimetry
  • Radiochemistry
  • NP-59
  • adrenal gland
  • aldosterone
  • cholesterol

Footnotes

  • Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: https://jnm.snmjournals.org/page/permissions.

  • Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development of Flourinated NP-59: A Revival of Cholesterol Utilization Imaging with PET
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Development of Flourinated NP-59: A Revival of Cholesterol Utilization Imaging with PET
Allen L Brooks, Wade Winton, Jenelle Stauff, Janna Arteaga, Bradford Henderson, Jeremy Niedbala, Peter Scott, Benjamin L Viglianti
Journal of Nuclear Medicine Apr 2022, jnumed.122.263864; DOI: 10.2967/jnumed.122.263864

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Development of Flourinated NP-59: A Revival of Cholesterol Utilization Imaging with PET
Allen L Brooks, Wade Winton, Jenelle Stauff, Janna Arteaga, Bradford Henderson, Jeremy Niedbala, Peter Scott, Benjamin L Viglianti
Journal of Nuclear Medicine Apr 2022, jnumed.122.263864; DOI: 10.2967/jnumed.122.263864
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
  • Correlation of 68Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer
  • 68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment
Show more Clinical Investigations (Human)

Clinical (Endocrine/Neuroendocrine)

  • Brown adipose tissue: a protective mechanism in “pre-prediabetes”?
  • Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors
Show more Clinical (Endocrine/Neuroendocrine)

Similar Articles

Keywords

  • Endocrine
  • Radiobiology/Dosimetry
  • Radiochemistry
  • NP-59
  • adrenal gland
  • aldosterone
  • cholesterol
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire